Pulmonary Manifestations of the Idiopathic Inflammatory Myopathies

被引：69

作者：

Kalluri, Meena ^{[1
]}

Oddis, Chester V. ^{[2
]}

机构：

[1] Univ Alberta, Div Pulm Med, Edmonton, AB, Canada

[2] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15260 USA

来源：

CLINICS IN CHEST MEDICINE | 2010年 / 31卷 / 03期

关键词：

Myositis; Pulmonary complications; Interstitial lung disease; INTERSTITIAL LUNG-DISEASE; TRANSFER-RNA-SYNTHETASE; RESOLUTION COMPUTED-TOMOGRAPHY; DISTINCT HLA-A; POLYMYOSITIS-DERMATOMYOSITIS; AMYOPATHIC DERMATOMYOSITIS; CYCLOPHOSPHAMIDE TREATMENT; CORTICOSTEROID-RESISTANT; IMMUNOGENETIC RISK; PROTECTIVE FACTORS;

D O I：

10.1016/j.ccm.2010.05.008

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary involvement in myositis includes interstitial lung disease (ILD), respiratory muscle weakness, aspiration, infections, and drug-induced disease. ILD may precede myositis, and results in increased morbidity and mortality rates. Initial evaluation should include pulmonary function tests and high-resolution computed tomography. Nonspecific interstitial pneumonia (NSIP) is the most common histologic pattern on lung biopsy. Treatment usually consists of a combination of steroids and other immunosuppressive agents, and the response depends on the clinical presentation and underlying histology.

引用

页码：501 / +

页数：13

共 84 条

[61] In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil [J].